Fujifilm ends delayed Avigan clinical test, looks to gov't application

Fujifilm Holdings Corp. said Monday it has completed delayed clinical tests of Avigan, a potential treatment for COVID-19, paving the way for the application of sales and production of the antivirus drug.Fujifilm Toyama Chemical Co., a subsidiary of Fujifilm Holdings, is conducting analysis of data from the tests to confirm the safety and efficacy of Avigan, which could be the third drug for the treatment of novel coronavirus patients if approved by the government.In Japan, the antiviral drug remdesivir developed by U.S. firm Gilead Sciences Inc. was given the green light in May, followed b…READ FULL ARTICLE